EPIAO (recombinant human erythropoietin biosimilar) / 3SBio - LARVOL DELTA

Hematoboost: Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative Anemia (clinicaltrials.gov) - P=N/A | N=419 | Not yet recruiting | Sponsor: West China Hospital

New trial • Surgery • Anemia • Hematological Disorders • Musculoskeletal Diseases • Orthopedics • Pain

Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study. (PubMed, Medicine (Baltimore)) - "EPIAO® demonstrated promising effectiveness and manageable safety in patients with end-stage renal disease on hemodialysis."

Clinical • Journal • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

BEAT_002: Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study) (clinicaltrials.gov) - P3 | N=207 | Completed | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting ➔ Completed

Trial completion • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

BEAT_001: Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) (clinicaltrials.gov) - P4; N=16; Terminated; Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.; N=96 ➔ 16; Recruiting ➔ Terminated

Clinical • Enrollment change • Trial termination • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

BEAT_002: Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study) (clinicaltrials.gov) - P3; N=198; Recruiting; Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.; Trial completion date: Dec 2019 ➔ Jul 2021; Trial primary completion date: Nov 2019 ➔ Oct 2020

Clinical • Trial completion date • Trial primary completion date • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

BEAT_001-Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) (clinicaltrials.gov) - P4; N=96; Not yet recruiting; Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

New P4 trial • Biosimilar • Chronic Kidney Disease • Renal Disease

Intraoperative Epiaortic Ultrasound for Traumatic Pseudoaneurysm of the Ascending Aorta. (PubMed) - Aorta (Stamford) - "Epiaortic ultrasound was employed and the aortic defect was identified and successfully repaired. This intraoperative imaging modality may play an increasing role in the identification of aortic pathology when visual inspection and other intraoperative imaging is insufficient."

Journal • Biosimilar

BEAT_001: Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) (clinicaltrials.gov) - P4; N=96; Recruiting; Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.; Not yet recruiting ➔ Recruiting; Trial primary completion date: Jan 2017 ➔ Jun 2018

Enrollment open • Trial primary completion date • Biosimilar • Chronic Kidney Disease • Gene Therapies • Renal Disease

3SBio: Interim Results 2016 Investor Conference Call (3SBio) - Anticipated completion of multi-center biosimilar clinical trials (NCT02522975) in Russia and Thailand by 2017

Anticipated trial completion date • Biosimilar